C-RAD jumps as FDA clears C-RAD Catalyst

First North listed C-RAD AB (STO:CRAD B) jumped 33% on Monday as the radiation therapy solutions developer could announce FDA approval of its C-RAD Catalyst advanced radiation therapy platform system. The Catalyst is approved to be used for positioning, motion control and respiratory gating. It consists of optical surface scanning and re-projection hardware and optimised software.

Approval for communication with the Varian MMI interface for auto setup and respiratory gating was also granted. The CEO Erik Hedlund said that the approval shall have a major impact on the company’s sales. The Catalyst system was released for sales in Europe last autumn and the second system in the US was just installed last week. In 2011 the company had sales of 14,9 million SEK and a loss after tax of 42,7 million.